ABVC BioPharma, Inc.

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.

Current securities

1. PRER14A filingSep 11, 2026
2. Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Regulation FD DisclosureAug 27, 2026
3. PRER14A filingAug 25, 2026
4. 424B4 filingAug 17, 2026
5. 424B4 filingAug 17, 2026